PetVivo Holdings (PETV)
OTHER OTC:PETV
Want to see PETV full AI Analyst Report?
Top Page
PetVivo Holdings
(OTC:PETV)
Select Model
Select Model
Rating:48Neutral
Price Target:
$0.79
▼(-29.38% Downside)
Action:ReiteratedDate:04/18/26
Overall score is held back primarily by weak financial performance (revenue decline, very large losses, and sustained cash burn). Technicals are mixed (better short-term trend vs weaker long-term trend), while valuation is constrained by negative earnings and no dividend. The latest earnings call provides a partial offset due to positive strategic developments, but lack of firm guidance and ongoing liquidity needs keep the score below average.
Positive Factors
SaaS high-margin opportunity
The exclusive 10-year AgenticPet license and PetVivo AI launch create a structural shift toward recurring, high-margin SaaS revenue. Recurring subscriptions with low CapEx materially improve unit economics, diversify revenue away from one-time device sales, and can sustainably lift overall gross margins if monetization executes as described.
Negative Factors
Sustained cash burn
Persistent negative operating and free cash flow indicate the company requires external capital to fund ongoing commercialization and R&D. Continued burn constrains strategic flexibility, forces prioritization of near-term survival over long-term investments, and increases execution risk if SaaS monetization or financing does not materialize on schedule.
Read all positive and negative factors
Positive Factors
Negative Factors
SaaS high-margin opportunity
The exclusive 10-year AgenticPet license and PetVivo AI launch create a structural shift toward recurring, high-margin SaaS revenue. Recurring subscriptions with low CapEx materially improve unit economics, diversify revenue away from one-time device sales, and can sustainably lift overall gross margins if monetization executes as described.
Read all positive factors
PetVivo Holdings (PETV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$27.31M
Dividend YieldN/A
Average Volume (3M)21.60K
Price to Earnings (P/E)―
Beta (1Y)0.02
Revenue Growth16.27%
EPS Growth17.37%
CountryUS
Employees20
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.40
Shares Outstanding35,017,418
10 Day Avg. Volume14,407
30 Day Avg. Volume21,604
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.91
Price to Sales (P/S)10.86
P/FCF Ratio-2.09
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue18.10
Enterprise Value/Gross Profit27.40
Enterprise Value/Ebitda-2.55
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PetVivo Holdings Business Overview & Revenue Model
Company Description
PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinar...
How the Company Makes Money
PetVivo generates revenue primarily from sales of its veterinary osteoarthritis treatment product (SPRYNG with OsteoCushion Technology). The company’s business model is centered on commercializing this product to veterinary customers, with revenue...
PetVivo Holdings Earnings Call Summary
Earnings Call Date:Feb 17, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Jun 25, 2026
Earnings Call Sentiment Positive
The call presented a strongly positive strategic and operational narrative: management secured transformative partnerships (exclusive AI licensing, major distributor and channel agreements), advanced R&D and international commercialization (Health Canada recognition, U.K. and Mexico distribution), and materially reduced liabilities (≈81% decline). These developments position the company for a recurring, high-margin SaaS revenue stream (PetVivo AI) that could complement device and biologic sales. Near-term financials remain challenging — modest revenue decline (−2% YoY for nine months), lower gross margins from product mix, ongoing operating losses (net loss $7.5M) and cash burn ($5.3M) leave liquidity and timing risks. Overall, the strategic progress and balance sheet improvements outweigh the current financial headwinds, suggesting a Positive sentiment with execution and monetization of AI and commercialization plans as key drivers to watch.Positive Updates
Strategic AI Partnership and New SaaS Platform Launch
Signed an exclusive 10-year white-label license with Digital Landia for AgenticPet AI and launched PetVivo AI (B2B SaaS). Beta testing reported 50%–90% reduction in veterinary customer acquisition costs (from typical $80–$400 down to <$43 per target) and the platform claims high recurring revenue potential with 80%–90% gross margins and low CapEx.
Negative Updates
Revenue Mix Shift and Spryng Sales Decline
Spryng sales for the nine months were $400,800 while PrecisePRP sales were $486,000. Overall revenue fell 2% YoY for the nine-month period, with Spryng sales negatively impacted by absence of prior-year promotional activity and some customers opting to use PrecisePRP alone rather than both products together.
Read all updates
Q3-2026 Updates
Positive
Negative
Strategic AI Partnership and New SaaS Platform Launch
Signed an exclusive 10-year white-label license with Digital Landia for AgenticPet AI and launched PetVivo AI (B2B SaaS). Beta testing reported 50%–90% reduction in veterinary customer acquisition costs (from typical $80–$400 down to <$43 per target) and the platform claims high recurring revenue potential with 80%–90% gross margins and low CapEx.
Read all positive updates
Company Guidance
The company did not provide firm forward revenue guidance on the call (management declined to reaffirm a prior ~$2.0–$2.5M fiscal-year estimate), but gave directional expectations and timing: PetVivo AI revenue is expected to begin contributing in the next fiscal year (post-April 1) with monetization “mid-year,” and will be a monthly recurring SaaS stream with very high gross margins (projected in the high 80%–90%) and low CapEx. Management highlighted product and balance-sheet metrics to frame outlook: nine‑month revenue of $887K (Spryng $400,800; PrecisePRP $486,000), gross profit $551,500 (62.2% margin), operating expenses $6.7M, operating loss $6.1M, net loss $7.5M ($0.27/share), net cash used in operations $5.3M, current assets $1.4M, current liabilities $980K, working capital $395K, subsequent inflows $477,500, and total liabilities down 81% to $1.0M (accounts payable down 53% to <$386K). On product economics and adoption, management cited PetVivo AI beta results (AgenticPet B2C: 1,000 users in <72 hours; 97% reported diagnostic accuracy), claimed 50%–90% reductions in customer acquisition cost (from typical $80–$400 down to < $43 per target), and referenced expected subscription conversion rates in the ~20%–25% range; however, no specific near‑term revenue or EPS targets were issued.PetVivo Holdings Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
38
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.11M | 1.13M | 968.71K | 917.16K | 115.59K | 12.58K |
| Gross Profit | 734.22K | 994.86K | 739.53K | 390.35K | -85.57K | 1.88K |
| EBITDA | -7.87M | -7.69M | -10.49M | -8.62M | -4.99M | -1.87M |
| Net Income | -9.93M | -8.40M | -10.96M | -8.70M | -4.94M | -3.75M |
Balance Sheet | ||||||
| Total Assets | 4.38M | 9.34M | 3.12M | 2.44M | 7.43M | 835.25K |
| Cash, Cash Equivalents and Short-Term Investments | 168.16K | 377.69K | 87.40K | 475.31K | 6.11M | 23.58K |
| Total Debt | 70.56K | 2.90M | 1.37M | 345.33K | 332.85K | 732.53K |
| Total Liabilities | 997.40K | 5.12M | 2.43M | 1.71M | 1.44M | 1.73M |
| Stockholders Equity | 3.38M | 4.22M | 685.95K | 725.02K | 5.99M | -896.98K |
Cash Flow | ||||||
| Free Cash Flow | -7.05M | -5.89M | -7.73M | -7.22M | -4.36M | -1.21M |
| Operating Cash Flow | -6.52M | -5.32M | -7.42M | -6.79M | -4.17M | -1.05M |
| Investing Cash Flow | -509.40K | -563.43K | -309.10K | -423.93K | -183.18K | -160.16K |
| Financing Cash Flow | 7.02M | 6.03M | 7.34M | 1.59M | 10.44M | 1.22M |
PetVivo Holdings Technical Analysis
Negative
1.12
Price Trends
0.75
Negative
0.92
Negative
0.97
Negative
Market Momentum
>-0.01
Negative
49.63
Neutral
91.25
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PETV, the sentiment is Negative. The current price of 1.12 is above the 20-day moving average (MA) of 0.74, above the 50-day MA of 0.75, and above the 200-day MA of 0.97, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.63 is Neutral, neither overbought nor oversold. The STOCH value of 91.25 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PETV.
PetVivo Holdings Risk Analysis
PetVivo Holdings disclosed 35 risk factors in its most recent earnings report. PetVivo Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
PetVivo Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $27.31M | -4.38 | -256.06% | ― | 16.27% | 17.37% | |
46 Neutral | $10.81M | -0.48 | -127.95% | ― | -14.14% | 53.49% | |
44 Neutral | $18.87M | -27.32 | -148.64% | ― | 8.23% | 51.64% | |
44 Neutral | $10.14M | -0.68 | -335.47% | ― | 16.05% | 27.95% | |
43 Neutral | $11.83M | -3.84 | 58.76% | ― | -52.57% | -5.36% |
* Healthcare Sector Average
PETV
PetVivo Holdings
0.78
0.16
25.81%
IRIX
Iridex
1.09
-0.06
-5.65%
LFWD
Lifeward
7.08
-9.00
-56.00%
VVOS
Vivos Therapeutics
0.74
-1.83
-71.05%
ALUR
Allurion Technologies
0.79
-1.56
-66.47%
NXL
Nexalin Technology, Inc.
0.38
-0.88
-69.84%
PetVivo Holdings Corporate Events
Private Placements and Financing
PetVivo Completes Private Equity Financing and Raises Capital
Positive
Apr 17, 2026
On April 15, 2026, PetVivo Holdings, Inc. received the final $600,000 installment under a March 13, 2026 subscription agreement, completing a $1,000,000 private equity financing. The company issued a total of 1,250,000 units at $0.80 per unit, eac...
Private Placements and Financing
PetVivo Holdings Announces New Equity Financing Agreement
Positive
Mar 16, 2026
On March 13, 2026, PetVivo Holdings, Inc. entered into a Subscription Agreement to raise $1,000,000 in equity financing in exchange for 1,250,000 shares of restricted common stock, receiving an initial $400,000 that day and expecting the remaining...
Business Operations and StrategyRegulatory Filings and Compliance
PetVivo Updates Investor Presentation and Disclosure Materials
Neutral
Mar 4, 2026
PetVivo Holdings, Inc. reported that its representatives plan to use an updated investor presentation when speaking at investor conferences and other forums, and may also post the materials on the company’s website. The presentation, furnish...
Executive/Board Changes
PetVivo Holdings Announces Board Change After Director Resignation
Neutral
Jan 29, 2026
On January 26, 2026, PetVivo Holdings, Inc. announced that director Spencer Breithaupt resigned from the company’s Board of Directors, with the company emphasizing that his departure did not stem from any disagreement over operations, polici...
Business Operations and StrategyRegulatory Filings and Compliance
PetVivo Holdings Announces New Investor Presentation Materials
Neutral
Jan 22, 2026
PetVivo Holdings, Inc. disclosed that its executives planned to present an investor deck at conferences and other forums, with the same material also to be made available on the company’s website. The slide presentation, furnished under Regu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.